• 6767 Bertner Ave, Mitchell Basic Science Research Building

    77030 Houston

    United States

  • 25725 Citations
  • 87 h-Index
1990 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Funda Meric-Bernstam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 32 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Mutation Medicine & Life Sciences
Breast Medicine & Life Sciences
Triple Negative Breast Neoplasms Medicine & Life Sciences
Recurrence Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1990 2019

8 Citations (Scopus)

Advances in HER2-targeted therapy: Novel agents and opportunities beyond breast and gastric cancer

Meric-Bernstam, F., Johnson, A. M., Ileana Dumbrava, E. E., Raghav, K. P. S., Balaji, K., Bhatt, M., Murthy, R. K., Rodon Ahnert, J. & Piha-Paul, S. A., Apr 1 2019, In : Clinical Cancer Research. 25, 7, p. 2033-2041 9 p.

Research output: Contribution to journalReview article

Stomach Neoplasms
Breast Neoplasms
Therapeutics
Biliary Tract Neoplasms
Neoplasms
3 Citations (Scopus)

Alpha particle radium 223 dichloride in high-risk osteosarcoma: A phase i dose escalation trial

Subbiah, V., Anderson, P. M., Kairemo, K., Hess, K., Huh, W. W., Ravi, V., Daw, N. C., Somaiah, N., Ludwig, J. A., Benjamin, R. S., Chawla, S., Hong, D. S., Meric-Bernstam, F., Ravizzini, G., Kleinerman, E., Macapinlac, H. & Rohren, E., Jan 1 2019, In : Clinical Cancer Research. 25, 13, p. 3802-3810 9 p.

Research output: Contribution to journalArticle

Open Access
Alpha Particles
Radium
Osteosarcoma
Neoplasm Metastasis
Technetium Tc 99m Medronate
3 Citations (Scopus)

A phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations

Voss, M. H., Hierro, C., Heist, R. S., Cleary, J. M., Meric-Bernstam, F., Tabernero, J., Janku, F., Gandhi, L., John Iafrate, A., Borger, D. R., Ishii, N., Hu, Y., Kirpicheva, Y., Nicolas-Metral, V., Pokorska-Bocci, A., Chessex, A. V., Zanna, C., Flaherty, K. T. & Baselga, J., Jan 1 2019, In : Clinical Cancer Research. 25, 9, p. 2699-2707 9 p.

Research output: Contribution to journalArticle

Open Access
Genes
Neoplasms
Hyperphosphatemia
Pharmacokinetics
Hyperamylasemia
2 Citations (Scopus)

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers (Nature, (2018), 554, 7691, (189-194), 10.1038/nature25475)

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J. & 27 others, Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J. & Solit, D. B., Feb 28 2019, In : Nature. 566, 7745, p. E11-E12

Research output: Contribution to journalComment/debate

Phosphotransferases
Neoplasms
Open Access
Internet
Observational Studies
Decision Making
Cross-Sectional Studies
Physicians